Asia Pacific Early Toxicity Testing Market is growing at a CAGR of 8.4%, to reach USD 158.51 million by 2023. Toxicity is an extent to which a chemical substance or a particular mixture of substances can damage a living organism. During the drug development of the diseases, it has been observed that nearly 28% of the drugs are failing in the later stages of the development causing huge financial losses in the pharmaceutical, food and other industries. So, to avoid this situation, early toxicity testing is implemented in which different types of toxic tests are conducted to remove the toxic substance in the early stages reducing the risk of late stage failure.
Some of the toxicity tests include carcinogenicity, acute toxicity tests, systemic toxicity, neurotoxicity and others. All these tests are performed in in-vivo, in-vitro or in-silico techniques. In-vivo toxicity testing is done on the living animals whereas in-vitro technique testing is performed in the laboratories using biochemical assays. In-silico technique testing includes the data analysis on the computer with the help of data mining and modelling tools. This toxicity tests can easily prove to the regulatory bodies that they are extremely safe to the human health without causing any adverse effects in the future.
The primary factor driving the Asia-Pacific early toxicity testing market is early toxicity tests helps in the decrease the risk of drug failure in the later stages of the disease. Other factors include increased investment in the R&D of toxic tests to develop new cell assays methods, growing awareness of the regulatory authorities, rise in the demand for early toxicity testing, technology advancements in the biotechnology and the favourable government funding in the biotech sector. However, side-effects like skin irritation, lack of awareness about toxicity and stringent government rules will hamper the market growth.
The Asia-Pacific Early Toxicity Testing Market is segmented on the basis of technique, assays, end-user and region. Depending on the technique, the market is segmented into In-vitro, In-vivo and In-Silico. In-vitro technique is further segmented into carcinogenicity, dermal toxicity, skin sensitization and irritation, systemic toxicity, ocular toxicity, neurotoxicity, organ toxicity, genotoxicity, and others. On the basis of assays, the market is segmented into cell-based ELISA and western blots, enzyme toxicity assays, receptor binding assays, bacterial toxicity assays, tissues culture assays and others. Based on the end-user, the market is segmented into pharmaceutical, food and beverages, chemical industry, diagnostics, cosmetics and others. The Asia-Pacific region is geographically segmented into China, India, Japan, South Korea, and Australia. Asia-Pacific is expected to have the highest CAGR in the coming years owing to the rise in disposable income and growing demographics.
Major companies in the Asia-Pacific Early Toxicity Testing Market are Covance, Thermo Fisher Scientifics, Quest Diagnostics Corporation, Agilent Technologies, Sigma Aldrich, BD Biosciences, Bio-Rad, Gene Logic, Accelrys and Charles River Laboratories.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Technique
5.1.1 Introduction
5.1.2 In-vitro
5.1.3 In-vivo
5.1.4 In-Silico
5.1.5 Y-o-Y Growth Analysis, By Technique
5.1.6 Market Attractiveness Analysis, By Technique
5.1.7 Market Share Analysis, By Technique
5.2 Assays
5.2.1 Introduction
5.2.2 Cell-Based ELISA and Western Blots
5.2.3 Enzyme Toxicity Assays
5.2.4 Receptor Binding Assays
5.2.5 Bacterial Toxicity Assays
5.2.6 Tissues Culture Assays
5.2.7 Other Assays
5.2.8 Y-o-Y Growth Analysis, By Assays
5.2.9 Market Attractiveness Analysis, By Assays
5.2.10 Market Share Analysis, By Assays
5.3 End-user
5.3.1 Introduction
5.3.2 Pharmaceutical
5.3.3 Food and Beverages
5.3.4 Chemical Industry
5.3.5 Diagnostics
5.3.6 Cosmetics
5.3.7 Others
5.3.8 Y-o-Y Growth Analysis, By End-user
5.3.9 Market Attractiveness Analysis, By End-user
5.3.10 Market Share Analysis, By End-user
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Technique
6.1.3.3 By Assays
6.1.3.4 By End-user
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Technique
6.1.4.3 By Assays
6.1.4.4 By End-user
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Technique
6.1.5.3 By Assays
6.1.5.4 By End-user
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Covance
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Thermo Fisher Scientific
8.3 Quest Diagnostics Corporation
8.4 Agilent Technologies
8.5 Sigma Aldrich
8.6 BD Biosciences
8.7 Bio-Rad
8.8 Gene Logic
8.9 Accelrys
8.10 Charles River Laboratories
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
